The College of American Pathologists (CAP) is seeking input from gastroenterologists as well as pathologists, oncologists and other stakeholders regarding an upcoming guideline on gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
The incidence of GEP-NETs, particularly among older adults, is increasing at a rate of 4% to 6% per year (Clin Gastroenterol Hepatol 2019;17[11]:2212-2217). The new guideline, being developed by a multidisciplinary panel, aims to provide evidence-based recommendations to improve diagnostic accuracy of GEP-NETs.
“Currently, there is a lack of clarity with the scoring of Ki67 staining and the best specimens to test,” according to a news release from CAP announcing the comment period. Overarching questions in the draft related to the best Ki67 scoring method for assigning grades in GEP-NETs and the best specimens—fine-needle aspirations, biopsies, and surgical resections of primary tumors and metastases—with which to grade these tumors.
CAP asks participants to review a draft of 10 recommendations graded as either “strong” or “conditional” and complete a survey assessing each statement, elaborating on any suggested modifications or points of disagreement.
The comment period will continue through April 7, and participants’ feedback will be posted weekly. Final recommendations will be formally published as a guideline in Archives of Pathology & Laboratory Medicine.
—GEN Staff
